Riskpilot← Back to searchSign inGet full accessPharmalex Nordic ApS
APSActiveCVR 37541540Lyngby Hovedgade 10CActivities of holding companies · NACE 6421Est. 20162 employees
Revenue 2025
DKK 3,5M
-13% vs 2024
EBITDA margin
47.1%
+174% vs 2024
Equity ratio
-22.7%
Financial strength
Net profit 2025
DKK 1,7M
+102% vs 2024
| Revenue | DKK 3,5M | -13% |
| EBITDA | DKK 1,7M | +174% |
| Net profit | DKK 1,7M | +102% |
| Total assets | DKK 202,9M | +4% |
| Equity | DKK -46M | +4% |
| Employees | 2 | — |
Legal name
Pharmalex Nordic ApS
CVR number
37541540
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
16. marts 2016
Share capital
DKK 25.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er som holdingselskab at drive virksomhed med konsulentydelser inden for medicinalindustrien og anden hermed beslægtet virksomhed.
Address
Lyngby Hovedgade 10C
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -20 | 100 | 1.891 | 2.373 | 2.608 | 3.352 | 3.283 | 2.786 | 4.083 | 3.534 |
| Staff expenses | -0 | -159 | -1.551 | -2.834 | -2.925 | -3.148 | -2.967 | -3.021 | -6.330 | -1.870 |
| EBITDA | -20 | -60 | 340 | -460 | -317 | 204 | 315 | -235 | -2.247 | 1.664 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -20 | -60 | 340 | -460 | -317 | 204 | 315 | -235 | -2.247 | 1.664 |
| Net financials | -162 | 555 | 62 | 2.098 | 3.531 | 4.512 | 105 | 4.555 | -88.680 | -499 |
| Profit before tax | -182 | 495 | 402 | 1.638 | 3.214 | 4.716 | 421 | 4.321 | -90.927 | 1.165 |
| Tax | -40 | -0 | -490 | -760 | -390 | -221 | -984 | -1.919 | -2.480 | -545 |
| Net profit | -142 | 495 | 892 | 2.398 | 3.604 | 4.937 | 1.405 | 6.239 | -88.448 | 1.710 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7.754 | 7.818 | 59.397 | 59.852 | 58.667 | 58.917 | 276.311 | 273.510 | 195.381 | 202.869 |
| Equity | 2.358 | 2.853 | 22.197 | 24.595 | 28.199 | 33.136 | 34.541 | 40.780 | -47.667 | -45.958 |
| Long-term debt | 4.350 | 4.906 | 36.644 | 34.178 | 22.113 | 20.945 | 182.885 | 223.926 | 230.061 | 246.043 |
| Short-term debt | 1.045 | 59 | 556 | 1.079 | 8.355 | 4.836 | 40.293 | 8.804 | 12.988 | 2.784 |
| Total debt | 5.396 | 4.965 | 37.200 | 35.257 | 30.468 | 25.780 | 223.179 | 232.730 | 243.049 | 248.827 |
EBITDA margin
47.1%
This company
15.8%
Market median
+198% vs market
20162025
Equity ratio
-22.7%
This company
38.2%
Market median
-159% vs market
20162025
Return on equity
170969100.0%
This company
18.4%
Market median
+929179791% vs market
20162025
Net profit margin
48.4%
This company
8.1%
Market median
+498% vs market
20162025
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20162025
Debt / equity
5.41×
This company
0.62×
Market median
-773% vs market
20162025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-03-16 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AL Management | Management | 2016 | — | — |
SB Management | Management | 2016 | — | — |
LM Management | Management | 2023 | — | — |
| Founder | 2016 | — | — | |
DR Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
CG Management | Management | 2023 | — | — |
TT Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
ÅP Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2023 | |
JAF INVEST ApS | Company | 20.0% | 20.0% | 2016 |
| Individual | 100.0% | 100.0% | 2020 | |
Vanturi ApS | Company | 5.0% | 5.0% | 2016 |
| Individual | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmalex Nordic ApS 
PharmaLex Denmark A/SBoard members of Pharmalex Nordic ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anette Langgaard Jacobsen | Management | 0 companies |
| Solveig Blomvik | Management | 0 companies |
| Laurent Maurice Robert Couston | Management | 0 companies |
| YES Multinational Holding Company GmbH | Founder | 0 companies |
| Dr. Raphael Troost | Chief Executive Officer | 0 companies |
| Christopher Gauglitz | Management | 0 companies |
| Torben Thers Nørgaard | Chief Executive Officer | 0 companies |
| Åsa Pihlblad | Chief Executive Officer | 0 companies |